Q2 2024 13F Holders as of 6/30/2024
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
181
-
Total 13F shares, excl. options
-
69.6M
-
Shares change
-
+325K
-
Total reported value, excl. options
-
$2.58B
-
Value change
-
+$1.54M
-
Put/Call ratio
-
2.03
-
Number of buys
-
102
-
Number of sells
-
-83
-
Price
-
$37.01
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q2 2024
227 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q2 2024.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 181 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 69.6M shares
.
Largest 10 shareholders include WELLINGTON MANAGEMENT GROUP LLP (8.08M shares), FMR LLC (7.83M shares), BlackRock Inc. (4.69M shares), VANGUARD GROUP INC (3.74M shares), Kynam Capital Management, LP (3.39M shares), EVENTIDE ASSET MANAGEMENT, LLC (3.33M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.17M shares), Polar Capital Holdings Plc (3.08M shares), Bellevue Group AG (2.97M shares), and STATE STREET CORP (2.66M shares).
This table shows the top 181 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.